1. Search Result
Search Result
Results for "

phosphoinositide

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

3

Peptides

1

Natural
Products

8

Recombinant Proteins

6

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100841

    3HPG

    Others Metabolic Disease
    (Rac)-3-Hydroxyphenylglycine is an phosphoinositide hydrolysis agonist . ACPD: I-aminocyclopcntane-1,3-dicarboxylic acid.
    (Rac)-3-Hydroxyphenylglycine
  • HY-13410
    Xanomeline oxalate
    1 Publications Verification

    LY246708 oxalate

    mAChR Neurological Disease
    Xanomeline oxalate (LY246708 oxalate) is a potent and selective muscarinic receptor agonist (SMRA) and stimulates phosphoinositide hydrolysis in vivo. Xanomeline oxalate can be used for the research of Alzheimer’s disease .
    Xanomeline oxalate
  • HY-107515
    LY367385
    2 Publications Verification

    mGluR Neurological Disease
    LY367385 is a highly selective and potent mGluR1a antagonist. LY367385 has an IC50 of 8.8 μM for inhibiting of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with >100 μM for mGlu5a. LY367385 has neuroprotective, anticonvulsant and antiepileptic effects .
    LY367385
  • HY-107515A
    LY367385 hydrochloride
    2 Publications Verification

    mGluR Neurological Disease
    LY367385 hydrochloride is a highly selective and potent mGluR1a antagonist. LY367385 hydrochloride has an IC50 of 8.8 μM for inhibiting of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with >100 μM for mGlu5a. LY367385 hydrochloride has neuroprotective, anticonvulsant and antiepileptic effects .
    LY367385 hydrochloride
  • HY-14440
    MP7
    1 Publications Verification

    PDK1 inhibitor

    PDK-1 Cancer
    MP7 (PDK1 inhibitor) is a phosphoinositide-dependent kinase-1 (PDK1) inhibitor.
    MP7
  • HY-145463

    5-HT Receptor Cardiovascular Disease
    α-Methylserotonin is a potent and selective agonist of 5-HT2 receptor.α-Methylserotonin is an analogue of serotonin formed in vivo from α-methyltryptophan.α-Methylserotonin mediates the lymphatic smooth muscle contraction and prevents the up-regulation of serotonin-receptor-mediated phosphoinositide hydrolysis .
    α-Methylserotonin
  • HY-P10105

    Akt Apoptosis Cancer
    TCL1(10-24) is a encompassing the betaA strand of human TCL1. TCL1(10-24) is a Akt inhibitor. TCL1(10-24) interacts with the Akt PH domain prevented phosphoinositide binding and hence inhibits membrane translocation and activation of Akt. TCL1(10-24) inhibits cellular proliferation and anti-apoptosis. TCL1(10-24) has tumor growth in vivo .
    TCL1(10-24)
  • HY-139880

    PI3K Cancer
    PI3Kγ inhibitor 5 is an inhibitor of phosphoinositide 3-kinase γ (PI3Kγ) with an IC50 value of 34 nM.
    PI3Kγ inhibitor 5
  • HY-125304

    Neurokinin Receptor Endocrinology
    L 363851 is a Neurokinin 2 receptor agonist, and induces the contractile response of tracheal smooth muscle devoid of epithelium (IC50 of 3.2 nM) and phosphoinositide hydrolysis (IC50 of 36 μM).
    L 363851
  • HY-101630A

    EGIS-3886 fumarate

    5-HT Receptor Others
    Deramciclane fumarate is an antagonist of 5-HT Receptor. Deramciclane fumarate is an inverse agonist of 5-HT2C Receptor with an IC50 of 168 nM. Deramciclane fumarate also decreases basal phosphoinositide hydrolysis .
    Deramciclane fumarate
  • HY-103566

    mGluR EGFR Neurological Disease
    LY456236 is a selective, non-competitive and orally active mGlu1 receptor antagonist that inhibits phosphoinositide hydrolysis with an IC50 of 0.145 μM. LY456236 also inhibits EGFR with an IC50 of 0.91 μM .
    LY456236
  • HY-101324

    CPP

    5-HT Receptor Neurological Disease
    MK-212 (CPP) is a centrally acting 5-HT1C/5-HT2 agonist. MK-212 can stimulate phosphoinositide hydrolysis in cerebral cortex .
    MK-212
  • HY-135464

    mGluR Neurological Disease
    (±)-LY367385 is the racemate of LY367385. LY367385 is a highly potent and selective mGluR1a antagonist. LY367385 has an IC50 of 8.8 μM for inhibits of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with > 100 μM for mGlu5a .
    (±)-LY367385
  • HY-101324A

    CPP monohydrochloride

    5-HT Receptor Neurological Disease
    MK-212 (CPP) monohydrochloride is a centrally acting 5-HT1C/5-HT2 agonist. MK-212 monohydrochloride can stimulate phosphoinositide hydrolysis in cerebral cortex .
    MK-212 monohydrochloride
  • HY-114457

    L-alpha-Phosphatidylinositol-4,5-bisphosphate

    PI3K Others
    Phosphatidylinositol 4,5-bisphosphate (L-alpha-Phosphatidylinositol-4,5-bisphosphate), a phospholipid component of cell membranes, is a substrate for phospholipase C (PLC) and phosphoinositide 3-kinase (PI3K) and as a primary messenger .
    Phosphatidylinositol 4,5-bisphosphate
  • HY-103030

    PI3K Cancer
    PI3K-IN-32 (compound 35) is a potent PI3K p110α inhibitor with an pIC50 of 6.85 .
    PI3K-IN-32
  • HY-139533

    Others Others
    Phosphatidylinositols, soya, sodium salts is a mixture of phosphatidylinositols. Phosphoinositides are lipids involved in the vesicular transport of proteins and lipids between the different compartments of eukaryotic cells. They act by recruiting and/or activating effector proteins and thus are involved in regulating various cellular functions, such as vesicular budding, membrane fusion and cytoskeleton dynamics .
    Phosphatidylinositols, soya, sodium salts
  • HY-110150
    UNC3230
    Maximum Cited Publications
    6 Publications Verification

    Others Inflammation/Immunology Cancer
    UNC3230 is a potent, selective and ATP-competitive PIP5K1C inhibitor with an IC50 of ~41 nM. UNC3230 also inhibits PIP4K2C and does not inhibit any of the other lipid kinases that regulate phosphoinositide levels. UNC3230 has antinociceptive and anticancer effects .
    UNC3230
  • HY-163360

    PI3K Cancer
    PI3Kα-IN-19 (Compound 1) is a PI3Kα inhibitor with a targeted binding site at the p110α catalytic subunit. PI3Kα is one of the most common dysregulated kinases used in cancer research .
    PI3Kα-IN-19
  • HY-P1096

    Cholecystokinin Receptor Metabolic Disease
    A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC50s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively .
    A71623
  • HY-14609
    MPEP Hydrochloride
    3 Publications Verification

    mGluR Neurological Disease
    MPEP Hydrochloride is a potent, selective, noncompetitive, orally active and systemically active mGlu5 receptor antagonist, with an IC50 of 36 nM for completely inhibiting quisqualate-stimulated phosphoinositide (PI) hydrolysis. MPEP Hydrochloride has anxiolytic-or antidepressant-like effects . MPEP (Hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MPEP Hydrochloride
  • HY-14609A
    MPEP
    3 Publications Verification

    mGluR Neurological Disease
    MPEP is a potent, selective, noncompetitive, orally active and systemically active mGlu5 receptor antagonist, with an IC50 of 36 nM for completely inhibiting quisqualate-stimulated phosphoinositide (PI) hydrolysis. MPEP has anxiolytic-or antidepressant-like effects . MPEP is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MPEP
  • HY-150135B

    Inositol 1,4,5-trisphosphate tripotassium; Ins(1,4,5)-P3 tripotassium

    Calcium Channel Neurological Disease
    D-myo-Inositol 1,4,5-trisphosphate tripotassium, a second messenger, elicits Ca 2+ mobilization. D-myo-Inositol 1,4,5-trisphosphate tripotassium inhibits the binding of phosphoinositide-specific phospholipase C-delta 1 (PLC-delta 1) to bilayer membranes composed of phosphatidylcholine (PC) and phosphatidylinositol 4,5-bisphosphate (PIP2) .
    D-myo-Inositol 1,4,5-trisphosphate tripotassium
  • HY-161366

    PI3K Cancer
    OMS14 is exhibits inhibitory activity for phosphoinositide 3-kinase γ (PI3Kγ) and PIK3CD/PIK3R1, which inhibits 19% PI3Kγ and 65% PIK3CD/PIK3R1 activity at 100 μM. OMS14 exhibits anticancer efficacy in various cancer cells .
    OMS14
  • HY-101115

    PI3K Cancer
    PI3K-IN-6 (compound 20a) is an oral active and highly selective phosphoinositide 3-kinase (PI3K) β/δ inhibitor, with IC50 values of 7.8 nM/5.3 nM for PI3K β/δ, respectively. PI3K-IN-6 (compound 20a) has potential top treat phosphatase and tensin homolog (PTEN) feficient tumors .
    PI3K-IN-6
  • HY-132231

    PI3K Apoptosis Cancer
    FD223 is a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. FD223 displays high potency (IC50=1 nM) and good selectivity over other isoforms (IC50s of 51 nM, 29 nM and 37 nM, respectively for α, β and γ). FD223 exhibits efficient inhibition of the proliferation of acute myeloid leukemia (AML) cell lines by suppressing p-AKT Ser473 thus causing G1 phase arrest during the cell cycle. FD223 has potential for the research of leukemia such as AML .
    FD223
  • HY-145086

    Others Metabolic Disease
    R-PSOP is highly potent and selective nonpeptidic NMUR2 antagonist. R-PSOP binds to NMUR2 with the Kis of 52 and 32 nM for the human and rat NMUR2, respectively. R-PSOP shows moderate CNS penetration. R-PSOP can be used for the research of the eating disorders, obesity, pain, and stress-related disorders .
    R-PSOP
  • HY-158688

    PI3K Inflammation/Immunology
    PI3Kδ-IN-21 (Compound 31) is a selective inhibitor for phosphoinositide 3-kinases δ (PI3Kδ), with an IC50 of 13.6 nM. PI3Kδ-IN-21 inhibits proliferation and differentation of T cells through PI3K/AKT/mTOR signaling pathway. PI3Kδ-IN-21 exhibits good pharmacokinetic characters in rat model, and attenuates the experimental autoimmune encephalomyelitis in myelin oligodendrocyte glycoprotein (MOG)-induced EAE model .
    PI3Kδ-IN-21
  • HY-107364

    Mol 211

    EGFR PI3K Cancer
    MTX-211 (Mol 211) is a dual inhibitor of EGFR and PI3K with IC50 values of <100 nM. MTX-211 can be used for the research of cancer and other diseases .
    MTX-211
  • HY-123541

    FGFR Tyrosinase Cancer
    Tec-IN-6 (compound 6) is a FGF2 binding to Tec kinase inhibitor, with an IC50 of 8.9 μM (His-FGF2/GST-NΔ173 Tec) .
    Tec-IN-6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: